Stocks to buy

The market tends to overreact to corporate financial results, leading many analysts on Wall Street to dub quarterly earnings reports the “silly season.” Many stocks rise or fall by 20% or more immediately after their quarterly prints are made public. These gyrations can lead to many great stocks becoming oversold. This has certainly been the
0 Comments
Are you in the market for oversold consumer stocks? You should be.  According to a Financial Times article from late July, investors have shunned consumer stocks over recession fears, which means there are opportunities to be had in this downtrodden segment of the market.    The Financial Times went on to report: “‘There’s a complete lack of
0 Comments
For investors seeking opportunities, undervalued robotics stocks offer potential for significant gains in a rebounding high-growth sector. Depressed valuations have been driven by tech sell-offs due to rising rates and macro uncertainties. This presents a chance to invest in innovative robotics companies at appealing prices. In the vast tech sector, robotics firms play a pivotal
0 Comments
Market volatility has struck again. Last week, U.S. equities continued their slide in August, leaving many market-watchers wondering whether or not equities in general had reached their peak. The attributed to this precipitous decline in share prices is most likely multi-faceted. There is the Federal Reserve, which still is not sure it will pause on interest rates
0 Comments
Earlier this month, I gave readers the rundown on Flexible Solutions International (NYSEAMERICAN:FSI) stock, an under-the-radar “green wave” play. With a low valuation, coupled with the company’s steady growth over the past few years, on the surface FSI stock appeared to be an opportunity worth exploring. After diving into the details, more stood out, suggesting that
0 Comments
Artificial intelligence is changing the drug-discovery process by making it much faster and cheaper.  Traditionally, most biotech stock drug candidates fail. Indeed, according to Nature, “An estimated 86% of drug candidates developed between 2000 and 2015 did not meet their stated endpoints.” And the well-respected consulting firm McKinsey reported that “Today, to discover and develop a
0 Comments